Founded in 1891, MSD is a leading science and technology company in healthcare, life sciences and pharmaceuticals. The company is among the top 10 globally with a revenue of US$59.3 billion in 2022.
With the global pharmaceutical industry expected to grow to around US$2.4 trillion in 2029 according to Fortune Business insights, we want to find out what’s next for the company, particularly here in Singapore.
On that note, MSD announced the opening of two manufacturing facilities to produce vaccines and biologics in Singapore back in October last year. But what is the status right now, and what does the recent rise in vaccine production facilities in Singapore say of the environment the country provides for pharmaceutical businesses?
On Under the Radar, Drive Time's finance presenter Chua Tian Tian sat down with Dr. Sheriff Abdullahi, Managing Director, Singapore, Malaysia & Brunei, MSD for more.